Close this search box.

Clinical Report: Obesity win for Structure, plus upbeat data for Annexon, Agios, Arrowhead, Ultragenyx, Intellia

ARTICLE | Product Development

Away from ASCO, handful of biotechs eye follow-ons or regularly submissions backed by new data

By BioCentury Staff

June 4, 2024 11:40 PM UTC

With most attention focused on the American Society of Clinical Oncology meeting, a handful of other biotechs had readouts — most of them positive — outside the cancer arena over the past few days.

Investor demand for obesity plays remains sky-high even if the data don’t appear to be best in class. That’s the message the market appeared to deliver on Monday after Structure Therapeutics Inc. (NASDAQ:GPCR) climbed 54% after reporting data for GSBR-1290 with good efficacy but, as of yet, a poor tolerability profile…